Daphne Board of Directors Office          The 7th Issue of 2010                March 18, 2010

        On March 18, 8 a.m., a delegation of 2 from the Ministry of Civil Affairs Department of Administration Regions' Planning & Naming visited Daphne under accompaniment of the prefectural and county officials. Mr. Dai, head of the Department of Administration Regions' Planning & Naming, and his companion had interest in the panax notoginseng industrial park and Daphne's panax notoginseng growing & product development.  
       At Daphne's product exhibition hall, Mr. Xiang Changwan, VP at Daphne, gave an introduction to Daphne's history and the panax notoginseng-based products. He highlighted the remarkable result of Daphne's panax notoginseng products in treatment of cardiac, cerebral and vascular diseases and the market outlook of the products. Currently, panax notoginseng is used in products of more than 1000 pharmaceutical factories in China. Daphne, as a pharmaceutical factory located in an area abundant in the panax notoginseng resource, enjoys a head start. Mr. Xiang especially presented Daphne's flagship product Thrombosis Tablets and two proprietary products recommended by the Ministry of Science & Technology and other four ministerial organizations as national highlighted new products - Qishengli and Qishengjing tablets made from monomer saponins Rg1 and Rb1 extracted from tPNS. Over the years, Daphne has stepped up research and development according to panax notoginseng's high medicinal value and succeeded in development of products with high technological level, such as new resource foods, active panax notoginseng and panax notoginseng energy booster. 
       In the end, Mr. Dai and the accompanying officials gave full affirmation and high comments on Daphne's development and contribution to the local panax notoginseng business.